Nuclear medicine: Radioactivity for diagnosis and therapy
Nuclear medicine is a growing specialized medical field in which radiopharmaceuticals, i.e. drugs associated to radioactivity, are used for diagnostic or therapeutic purposes. Since 1942, nuclear medicine has progressed in such a way that it became a major diagnostic tool in hospitals. The past ten...
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Les Ulis
EDP Sciences
[2020]
|
| Schlagworte: | |
| Online-Zugang: | FAB01 FAW01 FCO01 FHA01 FKE01 FLA01 UPA01 Volltext |
| Zusammenfassung: | Nuclear medicine is a growing specialized medical field in which radiopharmaceuticals, i.e. drugs associated to radioactivity, are used for diagnostic or therapeutic purposes. Since 1942, nuclear medicine has progressed in such a way that it became a major diagnostic tool in hospitals. The past ten years have seen the introduction of major technical breakthroughs which will considerably modify the landscape of cancer treatment. Once injected to the patient, the radiopharmaceutical drug aims at the tumour cell - including metastases - selectively, settles there, and emits radiation. Depending on the radiation type, the drug will either help identify the cells or destroy them. Applications are not limited to oncology; indeed, nuclear medicine has found interesting applications in cardiology and neurology as well. The new millennium saw the introduction of the Hybrid imaging technology PET/CT which combines the Positron Emission Tomography (PET) modality with conventional high quality x-ray imaging. It took another two years until PET could be combined with Magnetic Resonance Imaging (MRI) in the hybrid equipment PET/MR. New tracers (drugs for diagnosis) also came on the market with different diseases as targets, such as prostate cancer, neuroendocrine tumours, or Alzheimer's disease. But the recent introduction of radiotherapeutics in the treatment of cancer has brought major changes on the market, for they can be much more powerful and specific than chemotherapeutics or external radiation therapy. Combining radiodiagnostics to select positive responders to a treatment with efficient radiotherapeutics opens a highway for the development of theranostics, another word for personalized medicine. This scientific book aims to introduce nuclear medicine to a larger audience, pointing out, among other things, the difficulties met by both physicians and patients when trying to access new technologies. This second edition shows how much progress has been made over the past ten years since the original book was published, and how much can be expected for patients within the next few years |
| Beschreibung: | Description based on online resource; title from PDF title page (publisher's Web site, viewed 02. Feb 2021) |
| Beschreibung: | 1 online resource (216 pages) |
| ISBN: | 9782759821495 |
Internformat
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV047197861 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 210316s2020 |||| o||u| ||||||eng d | ||
| 020 | |a 9782759821495 |9 978-2-7598-2149-5 | ||
| 024 | 7 | |a 10.1051/978-2-7598-2149-5 |2 doi | |
| 035 | |a (ZDB-23-DGG)9782759821495 | ||
| 035 | |a (OCoLC)1242729959 | ||
| 035 | |a (DE-599)BVBBV047197861 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-1043 |a DE-1046 |a DE-858 |a DE-Aug4 |a DE-859 |a DE-860 |a DE-739 | ||
| 082 | 0 | |a 616.07575 | |
| 100 | 1 | |a Zimmermann, Richard |e Verfasser |4 aut | |
| 245 | 1 | 0 | |a Nuclear medicine |b Radioactivity for diagnosis and therapy |c Richard Zimmermann |
| 264 | 1 | |a Les Ulis |b EDP Sciences |c [2020] | |
| 264 | 4 | |c © 2017 | |
| 300 | |a 1 online resource (216 pages) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 500 | |a Description based on online resource; title from PDF title page (publisher's Web site, viewed 02. Feb 2021) | ||
| 520 | |a Nuclear medicine is a growing specialized medical field in which radiopharmaceuticals, i.e. drugs associated to radioactivity, are used for diagnostic or therapeutic purposes. Since 1942, nuclear medicine has progressed in such a way that it became a major diagnostic tool in hospitals. The past ten years have seen the introduction of major technical breakthroughs which will considerably modify the landscape of cancer treatment. Once injected to the patient, the radiopharmaceutical drug aims at the tumour cell - including metastases - selectively, settles there, and emits radiation. Depending on the radiation type, the drug will either help identify the cells or destroy them. Applications are not limited to oncology; indeed, nuclear medicine has found interesting applications in cardiology and neurology as well. | ||
| 520 | |a The new millennium saw the introduction of the Hybrid imaging technology PET/CT which combines the Positron Emission Tomography (PET) modality with conventional high quality x-ray imaging. It took another two years until PET could be combined with Magnetic Resonance Imaging (MRI) in the hybrid equipment PET/MR. New tracers (drugs for diagnosis) also came on the market with different diseases as targets, such as prostate cancer, neuroendocrine tumours, or Alzheimer's disease. But the recent introduction of radiotherapeutics in the treatment of cancer has brought major changes on the market, for they can be much more powerful and specific than chemotherapeutics or external radiation therapy. Combining radiodiagnostics to select positive responders to a treatment with efficient radiotherapeutics opens a highway for the development of theranostics, another word for personalized medicine. | ||
| 520 | |a This scientific book aims to introduce nuclear medicine to a larger audience, pointing out, among other things, the difficulties met by both physicians and patients when trying to access new technologies. This second edition shows how much progress has been made over the past ten years since the original book was published, and how much can be expected for patients within the next few years | ||
| 546 | |a In English | ||
| 650 | 4 | |a Medicine | |
| 650 | 4 | |a Nuclear | |
| 650 | 7 | |a MEDICAL / Allied Health Services / Medical Technology |2 bisacsh | |
| 650 | 4 | |a Nuclear medicine | |
| 856 | 4 | 0 | |u https://www.degruyter.com/isbn/9782759821495 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
| 912 | |a ZDB-23-DGG | ||
| 999 | |a oai:aleph.bib-bvb.de:BVB01-032602956 | ||
| 966 | e | |u https://www.degruyter.com/isbn/9782759821495 |l FAB01 |p ZDB-23-DGG |q FAB_PDA_DGG |x Verlag |3 Volltext | |
| 966 | e | |u https://www.degruyter.com/isbn/9782759821495 |l FAW01 |p ZDB-23-DGG |q FAW_PDA_DGG |x Verlag |3 Volltext | |
| 966 | e | |u https://www.degruyter.com/isbn/9782759821495 |l FCO01 |p ZDB-23-DGG |q FCO_PDA_DGG |x Verlag |3 Volltext | |
| 966 | e | |u https://www.degruyter.com/isbn/9782759821495 |l FHA01 |p ZDB-23-DGG |q FHA_PDA_DGG |x Verlag |3 Volltext | |
| 966 | e | |u https://www.degruyter.com/isbn/9782759821495 |l FKE01 |p ZDB-23-DGG |q FKE_PDA_DGG |x Verlag |3 Volltext | |
| 966 | e | |u https://www.degruyter.com/isbn/9782759821495 |l FLA01 |p ZDB-23-DGG |q FLA_PDA_DGG |x Verlag |3 Volltext | |
| 966 | e | |u https://www.degruyter.com/isbn/9782759821495 |l UPA01 |p ZDB-23-DGG |q UPA_PDA_DGG |x Verlag |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804182302191779840 |
|---|---|
| adam_txt | |
| any_adam_object | |
| any_adam_object_boolean | |
| author | Zimmermann, Richard |
| author_facet | Zimmermann, Richard |
| author_role | aut |
| author_sort | Zimmermann, Richard |
| author_variant | r z rz |
| building | Verbundindex |
| bvnumber | BV047197861 |
| collection | ZDB-23-DGG |
| ctrlnum | (ZDB-23-DGG)9782759821495 (OCoLC)1242729959 (DE-599)BVBBV047197861 |
| dewey-full | 616.07575 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.07575 |
| dewey-search | 616.07575 |
| dewey-sort | 3616.07575 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| discipline_str_mv | Medizin |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>04339nmm a2200517zc 4500</leader><controlfield tag="001">BV047197861</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">210316s2020 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9782759821495</subfield><subfield code="9">978-2-7598-2149-5</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1051/978-2-7598-2149-5</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-23-DGG)9782759821495</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1242729959</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV047197861</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-1043</subfield><subfield code="a">DE-1046</subfield><subfield code="a">DE-858</subfield><subfield code="a">DE-Aug4</subfield><subfield code="a">DE-859</subfield><subfield code="a">DE-860</subfield><subfield code="a">DE-739</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.07575</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Zimmermann, Richard</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Nuclear medicine</subfield><subfield code="b">Radioactivity for diagnosis and therapy</subfield><subfield code="c">Richard Zimmermann</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Les Ulis</subfield><subfield code="b">EDP Sciences</subfield><subfield code="c">[2020]</subfield></datafield><datafield tag="264" ind1=" " ind2="4"><subfield code="c">© 2017</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (216 pages)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Description based on online resource; title from PDF title page (publisher's Web site, viewed 02. Feb 2021)</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Nuclear medicine is a growing specialized medical field in which radiopharmaceuticals, i.e. drugs associated to radioactivity, are used for diagnostic or therapeutic purposes. Since 1942, nuclear medicine has progressed in such a way that it became a major diagnostic tool in hospitals. The past ten years have seen the introduction of major technical breakthroughs which will considerably modify the landscape of cancer treatment. Once injected to the patient, the radiopharmaceutical drug aims at the tumour cell - including metastases - selectively, settles there, and emits radiation. Depending on the radiation type, the drug will either help identify the cells or destroy them. Applications are not limited to oncology; indeed, nuclear medicine has found interesting applications in cardiology and neurology as well. </subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The new millennium saw the introduction of the Hybrid imaging technology PET/CT which combines the Positron Emission Tomography (PET) modality with conventional high quality x-ray imaging. It took another two years until PET could be combined with Magnetic Resonance Imaging (MRI) in the hybrid equipment PET/MR. New tracers (drugs for diagnosis) also came on the market with different diseases as targets, such as prostate cancer, neuroendocrine tumours, or Alzheimer's disease. But the recent introduction of radiotherapeutics in the treatment of cancer has brought major changes on the market, for they can be much more powerful and specific than chemotherapeutics or external radiation therapy. Combining radiodiagnostics to select positive responders to a treatment with efficient radiotherapeutics opens a highway for the development of theranostics, another word for personalized medicine. </subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">This scientific book aims to introduce nuclear medicine to a larger audience, pointing out, among other things, the difficulties met by both physicians and patients when trying to access new technologies. This second edition shows how much progress has been made over the past ten years since the original book was published, and how much can be expected for patients within the next few years</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">In English</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Medicine</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Nuclear</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Allied Health Services / Medical Technology</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Nuclear medicine</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.degruyter.com/isbn/9782759821495</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-23-DGG</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-032602956</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://www.degruyter.com/isbn/9782759821495</subfield><subfield code="l">FAB01</subfield><subfield code="p">ZDB-23-DGG</subfield><subfield code="q">FAB_PDA_DGG</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://www.degruyter.com/isbn/9782759821495</subfield><subfield code="l">FAW01</subfield><subfield code="p">ZDB-23-DGG</subfield><subfield code="q">FAW_PDA_DGG</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://www.degruyter.com/isbn/9782759821495</subfield><subfield code="l">FCO01</subfield><subfield code="p">ZDB-23-DGG</subfield><subfield code="q">FCO_PDA_DGG</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://www.degruyter.com/isbn/9782759821495</subfield><subfield code="l">FHA01</subfield><subfield code="p">ZDB-23-DGG</subfield><subfield code="q">FHA_PDA_DGG</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://www.degruyter.com/isbn/9782759821495</subfield><subfield code="l">FKE01</subfield><subfield code="p">ZDB-23-DGG</subfield><subfield code="q">FKE_PDA_DGG</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://www.degruyter.com/isbn/9782759821495</subfield><subfield code="l">FLA01</subfield><subfield code="p">ZDB-23-DGG</subfield><subfield code="q">FLA_PDA_DGG</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://www.degruyter.com/isbn/9782759821495</subfield><subfield code="l">UPA01</subfield><subfield code="p">ZDB-23-DGG</subfield><subfield code="q">UPA_PDA_DGG</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| id | DE-604.BV047197861 |
| illustrated | Not Illustrated |
| index_date | 2024-07-03T16:50:12Z |
| indexdate | 2024-07-10T09:05:23Z |
| institution | BVB |
| isbn | 9782759821495 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-032602956 |
| oclc_num | 1242729959 |
| open_access_boolean | |
| owner | DE-1043 DE-1046 DE-858 DE-Aug4 DE-859 DE-860 DE-739 |
| owner_facet | DE-1043 DE-1046 DE-858 DE-Aug4 DE-859 DE-860 DE-739 |
| physical | 1 online resource (216 pages) |
| psigel | ZDB-23-DGG ZDB-23-DGG FAB_PDA_DGG ZDB-23-DGG FAW_PDA_DGG ZDB-23-DGG FCO_PDA_DGG ZDB-23-DGG FHA_PDA_DGG ZDB-23-DGG FKE_PDA_DGG ZDB-23-DGG FLA_PDA_DGG ZDB-23-DGG UPA_PDA_DGG |
| publishDate | 2020 |
| publishDateSearch | 2020 |
| publishDateSort | 2020 |
| publisher | EDP Sciences |
| record_format | marc |
| spelling | Zimmermann, Richard Verfasser aut Nuclear medicine Radioactivity for diagnosis and therapy Richard Zimmermann Les Ulis EDP Sciences [2020] © 2017 1 online resource (216 pages) txt rdacontent c rdamedia cr rdacarrier Description based on online resource; title from PDF title page (publisher's Web site, viewed 02. Feb 2021) Nuclear medicine is a growing specialized medical field in which radiopharmaceuticals, i.e. drugs associated to radioactivity, are used for diagnostic or therapeutic purposes. Since 1942, nuclear medicine has progressed in such a way that it became a major diagnostic tool in hospitals. The past ten years have seen the introduction of major technical breakthroughs which will considerably modify the landscape of cancer treatment. Once injected to the patient, the radiopharmaceutical drug aims at the tumour cell - including metastases - selectively, settles there, and emits radiation. Depending on the radiation type, the drug will either help identify the cells or destroy them. Applications are not limited to oncology; indeed, nuclear medicine has found interesting applications in cardiology and neurology as well. The new millennium saw the introduction of the Hybrid imaging technology PET/CT which combines the Positron Emission Tomography (PET) modality with conventional high quality x-ray imaging. It took another two years until PET could be combined with Magnetic Resonance Imaging (MRI) in the hybrid equipment PET/MR. New tracers (drugs for diagnosis) also came on the market with different diseases as targets, such as prostate cancer, neuroendocrine tumours, or Alzheimer's disease. But the recent introduction of radiotherapeutics in the treatment of cancer has brought major changes on the market, for they can be much more powerful and specific than chemotherapeutics or external radiation therapy. Combining radiodiagnostics to select positive responders to a treatment with efficient radiotherapeutics opens a highway for the development of theranostics, another word for personalized medicine. This scientific book aims to introduce nuclear medicine to a larger audience, pointing out, among other things, the difficulties met by both physicians and patients when trying to access new technologies. This second edition shows how much progress has been made over the past ten years since the original book was published, and how much can be expected for patients within the next few years In English Medicine Nuclear MEDICAL / Allied Health Services / Medical Technology bisacsh Nuclear medicine https://www.degruyter.com/isbn/9782759821495 Verlag URL des Erstveröffentlichers Volltext |
| spellingShingle | Zimmermann, Richard Nuclear medicine Radioactivity for diagnosis and therapy Medicine Nuclear MEDICAL / Allied Health Services / Medical Technology bisacsh Nuclear medicine |
| title | Nuclear medicine Radioactivity for diagnosis and therapy |
| title_auth | Nuclear medicine Radioactivity for diagnosis and therapy |
| title_exact_search | Nuclear medicine Radioactivity for diagnosis and therapy |
| title_exact_search_txtP | Nuclear medicine Radioactivity for diagnosis and therapy |
| title_full | Nuclear medicine Radioactivity for diagnosis and therapy Richard Zimmermann |
| title_fullStr | Nuclear medicine Radioactivity for diagnosis and therapy Richard Zimmermann |
| title_full_unstemmed | Nuclear medicine Radioactivity for diagnosis and therapy Richard Zimmermann |
| title_short | Nuclear medicine |
| title_sort | nuclear medicine radioactivity for diagnosis and therapy |
| title_sub | Radioactivity for diagnosis and therapy |
| topic | Medicine Nuclear MEDICAL / Allied Health Services / Medical Technology bisacsh Nuclear medicine |
| topic_facet | Medicine Nuclear MEDICAL / Allied Health Services / Medical Technology Nuclear medicine |
| url | https://www.degruyter.com/isbn/9782759821495 |
| work_keys_str_mv | AT zimmermannrichard nuclearmedicineradioactivityfordiagnosisandtherapy |